Agenus(US:AGEN) Prnewswireยท2024-09-16 09:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1]. Group 1 - The class action alleges that the combination therapy of botensilimab and balstilimab was less effective than previously claimed by the company [1]. - The complaint states that the clinical results and regulatory and commercial prospects of botensilimab and balstilimab were overstated [1]. - As a result of these allegations, the company's public statements were deemed materially false and misleading throughout the relevant period [1]. Group 2 - Shareholders who purchased shares of Agenus during the specified class period are encouraged to register for the class action, with a deadline of November 5, 2024, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3 - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].